- Global Pharma News & Resources

Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

LONDON, August 5, 2019 – Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler (“DPI”) formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). All of the primary and secondary lung function endpoints were met in the Phase 2 trial 


·         Primary endpoint met: highly statistically significant and clinically meaningful dose-dependent improvement in lung function

·         Secondary lung function endpoints met, data supportive of twice daily dosing and ensifentrine well tolerated at all dose levels

·         Delivery via DPI could substantially expand the clinical utility and commercial opportunity for ensifentrine in COPD

·         Conference call and webcast to be held tomorrow (Tuesday, August 6) at 8 am EDT / 1 pm BST to discuss the Company’s second quarter financial results and the study data

The Phase 2 trial met all of its primary and secondary lung function endpoints with ensifentrine delivered in a DPI format. The magnitude of improvement in lung function and duration of action were highly statistically significant and support twice daily dosing of ensifentrine for the treatment of COPD.

·         Primary endpoint met: peak FEV1[1] corrected for placebo showed improvements over baseline of 102 mL for the 150 µg[2] dose, 175 mL for the 500 µg dose, 180 mL for the 1500 µg dose and 260 mL for the 3000 µg dose, (p<0.0001 for all doses), all highly statistically significant.

·         Secondary endpoints met:

o   Statistically significant improvements in average FEV1 over 12 hours were observed over 7 days with all doses
(average FEV1 AUC(0-12hr)[3] corrected for placebo: 36 mL for the 150 µg dose, 90 mL for the 500 µg dose, 80 mL for the 1500 µg dose and 147 mL for the 3000 µg dose; p<0.05 for all doses).

o   Ensifentrine in a handheld dry powder format was well tolerated at all doses with an adverse event profile similar to placebo. The safety profile was comparable to that observed in prior studies with nebulized ensifentrine.

“Achieving a bronchodilator response of this magnitude in COPD patients is clinically meaningful and very encouraging,” commented Joseph A Boscia, III, MD a Pulmonary Physician and Principle Investigator at Vitalink Research-Union, South Carolina. “This highlights the potential for ensifentrine’s unique mechanism of action to provide lung function improvement and meet the urgent clinical need for new treatments for patients with this progressive and debilitating disease."

Jan-Anders Karlsson, PhD, CEO of Verona Pharma, said: “These very promising data with the DPI formulation support our view that ensifentrine is an effective bronchodilator in COPD patients, whether administered as a dry powder via a handheld inhaler or as a suspension via a nebulizer. Our proof-of-concept dry powder formulation can be adapted to different DPI devices used in the market. Millions of patients prefer to use a handheld device, and these data significantly expand ensifentrine’s commercial potential. We plan to complete further development and commercialization of the DPI formulation with a partner and these clinical data strongly support this opportunity."In addition to the DPI formulation of ensifentrine, Verona Pharma is developing a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine and expects to report initial single dose data using this widely used handheld inhaler format in the second half of 2019, with final multiple dose data from a one week study expected in the first quarter of 2020. Progression of the nebulized suspension formulation of ensifentrine continues, with data from the ongoing Phase 2b clinical trial expected around year end. Verona Pharma anticipates progressing the ensifentrine nebulizer formulation into Phase 3 clinical trials in 2020.

Study Design

The randomized, double-blind, placebo-controlled, two-part Phase 2 trial ( NCT04027439) enrolled 35 patients with moderate-to-severe COPD at one US site to investigate the efficacy and safety of a DPI formulation of ensifentrine compared to placebo. In Part A of the trial, patients received a single dose of one (out of five) dosage strengths of ensifentrine (150 µg, 500 µg, 1500 µg, 3000 µg, or 6000 µg) or placebo. In March 2019, Verona Pharma reported positive interim efficacy and safety data from the first part of the trial, triggering initiation of the second part of the trial.

In Part B of the trial, patients were randomized to receive one of four dose levels (150 µg, 500 µg, 1500 µg, or 3000 µg) of ensifentrine DPI formulation or placebo, administered twice daily over one week. All patients received each dose level and placebo over five seven-day treatment periods. The primary endpoint was improvement in peak bronchodilator effect of repeat doses of ensifentrine delivered via DPI compared to placebo, as measured by FEV1. Secondary objectives included evaluating the safety, tolerability and bronchodilator profile of repeat doses of ensifentrine administered by DPI, as well as the pharmacokinetic profile, onset of action, and the amount of rescue medication use during treatment periods.

Data on the primary and secondary lung function and pharmacokinetic profile endpoints have been received and all endpoints were met. Data on the amount of rescue medication use during treatment periods are expected later this month

Conference Call

Verona Pharma will host an investment community conference call tomorrow (Tuesday, August 6) at 8 am EDT / 1 pm BST to discuss the second quarter financial results and the study data.

Analysts and investors may participate in the conference call using the conference ID: 7433729 and dialing the following numbers:

  • 866-940-4574 or 409-216-0615 for callers in the United States
  • 0800 028 8438 for callers in the United Kingdom
  • 0800 181 5287 for callers in Germany


Those interested in listening to the conference call live via the internet may do so by visiting the “Events and Presentations” page on the “Investors” section of Verona Pharma’s website at and clicking on the webcast link. Slides highlighting the top-line data will also be posted to the “Events and Presentations” page.

[1] FEV1: forced expiratory volume in one second, a standard measure of lung function

[2] µg: microgram, or mcg

[3] FEV1 AUC(0-12hr: area under the curve 0-12 hours calculated using the trapezoidal rule, divided by the observation time (12h) to report in mL, a measure of the aggregate effect over 12 hours


Editor Details

  • Company:
    • Verona Pharma plc
  • Name:
    • Verona Pharma plc
Last Updated: 05-Aug-2019